RetroNectin 激活细胞因子诱导的杀伤细胞疗法在转移性脑肿瘤患者中的疗效。

Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients.

机构信息

Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

出版信息

Oncol Res Treat. 2015;38(4):160-5. doi: 10.1159/000380890. Epub 2015 Mar 16.

DOI:10.1159/000380890

PMID:25877939

Abstract

BACKGROUND

The aim of this study was to investigate the clinical efficacy of RetroNectin-activated cytokine-induced killer cell (R-CIK) therapy following conventional therapies in patients with metastatic brain tumors.

METHODS

This study included 20 patients with metastatic brain tumors. Patients received R-CIK therapy following conventional therapies (including chemotherapy and target therapy). Progression-free survival (PFS), overall survival (OS), and prognostic factors were evaluated.

RESULTS

Of the 4 breast cancer patients in our cohort, 2 remained alive and 2 died. Of the 14 non-small cell lung cancer (all adenocarcinoma) patients, 3 had a partial response, 8 had stable disease, and 3 had progressive disease after receiving R-CIKs. The overall response rate was 21.4% (3/14), and the disease control rate was 78.6% (11/14). The median PFS and OS were 7.7 months (95% confidence interval (CI) 3-16.5 months) and 12.6 months (95% CI 6-21 months), respectively.

CONCLUSION

R-CIKs combined with conventional therapies could improve the prognosis of metastatic brain tumor patients, especially of those with adenocarcinoma of the lung.

摘要

背景

本研究旨在探讨 RetroNectin 激活细胞因子诱导的杀伤细胞（R-CIK）治疗在转移性脑肿瘤患者常规治疗后的临床疗效。

方法

本研究纳入 20 例转移性脑肿瘤患者。患者在常规治疗（包括化疗和靶向治疗）后接受 R-CIK 治疗。评估无进展生存期（PFS）、总生存期（OS）和预后因素。

结果

在我们的队列中，4 例乳腺癌患者中有 2 例存活，2 例死亡。14 例非小细胞肺癌（均为腺癌）患者中，接受 R-CIK 治疗后，3 例部分缓解，8 例疾病稳定，3 例疾病进展。总缓解率为 21.4%（3/14），疾病控制率为 78.6%（11/14）。中位 PFS 和 OS 分别为 7.7 个月（95%CI 3-16.5 个月）和 12.6 个月（95%CI 6-21 个月）。